Eris Lifesciences acquires trademark anti-diabetes drug Zomelis from Novartis for Indian market

Eris Lifesciences acquires trademark anti-diabetes drug Zomelis from Novartis for Indian market

Eris Lifesciences has announced that the company has acquired trademark for Novartis Ag’s anti-diabetic medication, Zomelis, for USD 13 million on 3rd December, 2019.

The vildagliptin based drug which is used to treat type 2 diabetes mellitus comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors.

The drug will start its commercialisation in Indian market from December 10, 2019, declared the company.

The company claims itself as one of the top 10 players in the anti-diabetes drugs segment in the Indian Pharmaceutical Market, referring to data by pharmaceutical market research company AIOCD-AWACS for October, 2019.

Eris Lifesciences focuses on chronic and acute categories of the Indian branded formulations market involving cardiovascular, anti–diabetes, vitamins, gastroenterology, gynaecology, IVF and CNS.